Long-term use of antipsychotics among community-dwelling persons with Alzheimer's disease: A nationwide register-based study

European Neuropsychopharmacology

Volumn 25, Issue 10, 2015, Pages 1706-1713

  Koponen, Marjaana ^a   Taipale, Heidi ^a   Tanskanen, Antti ^b,c   Tolppanen, Anna Maija ^a   Tiihonen, Jari ^a,b,c   Ahonen, Riitta ^a   Hartikainen, Sirpa ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KAROLINSKA INSTITUTE   (Sweden)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Alzheimer's disease; Antipsychotic drugs; Pharmacoepidemiology

Indexed keywords

HALOPERIDOL; MELPERONE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; NEUROLEPTIC AGENT;

AGED; ALZHEIMER DISEASE; ARTICLE; COHORT ANALYSIS; COMMUNITY LIVING; DRUG USE; FEMALE; FINLAND; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PHARMACOEPIDEMIOLOGY; PREVALENCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RISK ASSESSMENT; TREATMENT DURATION; REGISTER; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; FEMALE; FINLAND; FOLLOW-UP STUDIES; HALOPERIDOL; HUMANS; MALE; PREVALENCE; QUETIAPINE FUMARATE; REGISTRIES; RISPERIDONE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84943355425     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2015.07.008     Document Type: Article

References (45)

1. Azermai M., Petrovic M., Elseviers M.M., Bourgeois J., Van Bortel L.M., Vander Stichele R.H. Systematic appraisal of dementia guidelines for the management of behavioural and psychological symptoms. Ageing Res. Rev. 2012, 11:78-86.
2. Ballard C., Hanney M.L., Theodoulou M., Douglas S., McShane R., Kossakowski K., Gill R., Juszczak E., Yu L.M., Jacoby R. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol. 2009, 8:151-157. DART-AD investigators.
3. Barnes T.R., Banerjee S., Collins N., Treloar A., McIntyre S.M., Paton C. Antipsychotics in dementia: prevalence and quality of antipsychotic drug prescribing in UK mental health services. Br. J. Psychiatry 2012, 201:221-226.
4. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 1987, 40:373-383.
5. Declercq T., Petrovic M., Azermai M., Vander Stichele R., De Sutter A.I., van Driel M.L., Christiaens T. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst. Rev. 2013, 3:CD007726.
6. Eustace A., Coen R., Walsh C., Cunningham C.J., Walsh J.B., Coakley D., Lawlor B.A. A longitudinal evaluation of behavioural and psychological symptoms of probable Alzheimer's disease. Int. J. Geriatr. Psychiatry 2002, 17:968-973.
7. Finnish Medical Society Duodecim, Helsinki, 2010. Current care: Memory disorders (in Finnish with English summary). Available at (accessed 07.10.14). http://www.kaypahoito.fi.
8. Gill S.S., Rochon P.A., Herrmann N., Lee P.E., Sykora K., Gunraj N., Normand S.L., Gurwitz J.H., Marras C., Wodchis W.P., Mamdani M. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. Br. Med. J. 2005, 330(7489):445.
9. Gill S.S., Bronskill S.E., Normand S.L., Anderson G.M., Sykora K., Lam K., Bell C.M., Lee P.E., Fischer H.D., Herrmann N., Gurwitz J.H., Rochon P.A. Antipsychotic drug use and mortality in older adults with dementia. Ann. Intern. Med. 2007, 146:775-786.
10. Gustafsson M., Karlsson S., Lövheim H. Inappropriate long-term use of antipsychotic drugs is common among people with dementia living in specialized care units. BMC Pharmacol. Toxicol. 2013, 14:10. 10.1186/2050-6511-14-10.
11. Guthrie B., Clark S.A., McCowan C. The burden of psychotropic drug prescribing in people with dementia: a population database study. Age Ageing 2010, 39:637-642.
12. Hermes E.D., Sernyak M., Rosenheck R. Use of second-generation antipsychotic agents for sleep and sedation: a provider survey. Sleep 2013, 36:597-600.
13. Jalbert J.J., Eaton C.B., Miller S.C., Lapane K.L. Antipsychotic use and the risk of hip fracture among older adults afflicted with dementia. J. Am. Med. Dir. Assoc. 2010, 11:120-127.
14. Kales H.C., Kim H.M., Zivin K., Valenstein M., Seyfried L.S., Chiang C., Cunningham F., Schneider L.S., Blow F.C. Risk of mortality among individual antipsychotics in patients with dementia. Am. J. Psychiatry 2012, 169:71-79.
15. Koponen, M., Tolppanen, A.M., Taipale, H., Tanskanen, A., Tiihonen, J., Johnell, K., Fastbom, J., Ahonen, R., Hartikainen, S., 2015. Incidence of antipsychotic use in relation to diagnosis of Alzheimer's disease among community-dwelling persons. Br. J. Psychiatry, in press.
16. Laitinen M.L., Bell J.S., Lavikainen P., Lönnroos E., Sulkava R., Hartikainen S. Nationwide study of antipsychotic use among community-dwelling persons with Alzheimer's disease in Finland. Int. Psychogeriatr. 2011, 23:1623-1631.
17. Leucht S., Cipriani A., Spineli L., Mavridis D., Orey D., Richter F., Samara M., Barbui C., Engel R.R., Geddes J.R., Kissling W., Stapf M.P., Lassig B., Salanti G., Davis J.M. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013, 382:951-962.
18. Liperoti R., Onder G., Landi F., Lapane K.L., Mor V., Bernabei R., Gambassi G. All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study. J. Clin. Psychiatry 2009, 70:1340-1347.
19. Lonergan E., Britton A.M., Luxenberg J., Wyller T. Antipsychotics for delirium. Cochrane Database Syst. Rev. 2007, (2):CD005594.
20. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
21. Nobili A., Pasina L., Trevisan S., Riva E., Lucca U., Tettamanti M., Matucci M., Tarantola M. Use and misuse of antipsychotic drugs in patients with dementia in Alzheimer special care units. Int. Clin. Psychopharmacol. 2009, 24:97-104.
22. Purhonen M., Koponen H., Tiihonen J., Tanskanen A. Outcome of patients after market withdrawal of thioridazine: a retrospective analysis in a nationwide cohort. Pharmacoepidemiol. Drug Saf. 2012, 21:1227-1231.
23. Puyat J.H., Law M.R., Wong S.T., Sutherland J.M., Morgan S.G. The essential and potentially inappropriate use of antipsychotics across income groups: an analysis of linked administrative data. Can. J. Psychiatry 2012, 57:488-495.
24. Rahkonen T., Luukkainen-Markkula R., Paanila S., Sivenius J., Sulkava R. Delirium episode as a sign of undetected dementia among-community dwelling elderly subjects: a 2 year follow up study. J. Neurol. Neurosurg. Psychiatry 2000, 69:519-521.
25. Rattinger G.B., Burcu M., Dutcher S.K., Chhabra P.T., Rosenberg P.B., Simoni-Wastila L., Franey C.S., Walker L.D., Zuckerman I.H. Pharmacotherapeutic management of dementia across settings of care. J. Am. Geriatr. Soc. 2013, 61:723-733.
26. Rea R.S., Battistone S., Fong J.J., Devlin J.W. Atypical antipsychotics versus haloperidol for treatment of delirium in acutely ill patients. Pharmacotherapy 2007, 27:588-594.
27. Rikala M., Hartikainen S., Sulkava R., Korhonen M.J. Validity of the Finnish Prescription Register for measuring psychotropic drug exposures among elderly finns: a population-based intervention study. Drugs Aging 2010, 27:337-349.
28. Rockwood K., Cosway S., Carver D., Jarrett P., Stadnyk K., Fisk J. The risk of dementia and death after delirium. Age Ageing 1999, 28:551-556.
29. Rojas-Fernandez C., Mikhail M., Brown S.G. Psychotropic and cognitive-enhancing medication use and its documentation in contemporary long-term care practice. Ann. Pharmacother. 2014, 48:438-446.
30. Ryu S.H., Katona C., Rive B., Livingston G. Persistence of and changes in neuropsychiatric symptoms in Alzheimer disease over 6 months: the LASER-AD study. Am. J. Geriatr. Psychiatry 2005, 13:976-983.
31. Schneeweiss S., Setoguchi S., Brookhart A., Dormuth C., Wang P.S. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 2007, 176:627-632.
32. Schneider L.S., Dagerman K.S., Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. J. Am. Med. Assoc. 2005, 294:1934-1943.
33. Schulze J., Glaeske G., van den Bussche H., Kaduszkiewicz H., Koller D., Wiese B., Hoffmann F. Prescribing of antipsychotic drugs in patients with dementia: a comparison with age-matched and sex-matched non-demented controls. Pharmacoepidemiol. Drug Saf. 2013, 22:1308-1316.
34. Selbæk G., Kirkevold Ø., Engedal K. The course of psychiatric and behavioral symptoms and the use of psychotropic medication in patients with dementia in Norwegian nursing homes - a 12-month follow-up study. Am. J. Geriatr. Psychiatry 2008, 16:528-536.
35. Taipale H., Koponen M., Tanskanen A., Tolppanen A.M., Tiihonen J., Hartikainen S. Antipsychotic polypharmacy among a nationwide sample of community-dwelling persons with alzheimer's disease. J. Alzheimers Dis. 2014, 41:1223-1228.
36. Taipale H., Koponen M., Tanskanen A., Tolppanen A.M., Tiihonen J., Hartikainen S. Antipsychotic doses among community-dwelling persons with Alzheimer disease in Finland. J. Clin. Psychopharmacol. 2014, 34:435-440.
37. Taipale H., Tanskanen A., Koponen M., Tolppanen A.M., Tiihonen J., Hartikainen S. Antidementia drug use among community-dwelling individuals with Alzheimer's disease in Finland: a nationwide register-based study. Int. Clin. Psychopharmacol. 2014, 29:216-223.
38. Tanskanen A., Taipale H., Koponen M., Tolppanen A.M., Hartikainen S., Ahonen R., Tiihonen J. From prescription drug purchases to drug use periods - a second generation method (PRE2DUP). BMC Med. Inform. Decis. Mak. 2015, 15. 10.1186/s12911-015-0140-z.
39. Tiihonen J., Lönnqvist J., Wahlbeck K., Klaukka T., Niskanen L., Tanskanen A., Haukka J. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009, 374:620-627.
40. Tolppanen A.M., Taipale H., Koponen M., Lavikainen P., Tanskanen A., Tiihonen J., Hartikainen S. Use of existing data sources in clinical epidemiology: Finnish health care registers in Alzheimer's disease research - the medication use among persons with Alzheimer's disease (MEDALZ-2005) study. Clin. Epidemiol. 2013, 5:277-285.
41. Wang P.S., Schneeweiss S., Avorn J., Fischer M.A., Mogun H., Solomon D.H., Brookhart M.A. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N. Engl. J. Med. 2005, 353:2335-2341.
42. Wetzels R.B., Zuidema S.U., de Jonghe J.F., Verhey F.R., Koopmans R.T. Prescribing pattern of psychotropic drugs in nursing home residents with dementia. Int. Psychogeriatr. 2011, 23:1249-1259.
43. WHO Collaborating Centre for Drug Statistics Methodology, 2009. Defined daily dose. Available at (accessed 07.10.14). http://www.whocc.no/ddd/definition_and_general_considera/.
44. WHO Collaborating Centre for Drug Statistics Methodology, 2014. The Anatomical Therapeutic Chemical Classification System. Available at (accessed 07.10.14). http://www.whocc.no/atc_ddd_index/.
45. Wood-Mitchell A., James I.A., Waterworth A., Swann A., Ballard C. Factors influencing the prescribing of medications by old age psychiatrists for behavioural and psychological symptoms of dementia: a qualitative study. Age Ageing 2008, 37:547-552.